Evidence map›Paper›PMID 34023137›Full record

ArticleVaccine2021

Strengthening and accelerating SARS-CoV-2 vaccine safety surveillance through registered pre-approval rollout after challenge tests.

Nir Eyal, Tobias Gerhard, Brian L Strom

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 2 countries.

Nir EyalCenter for Population-Level Bioethics and Department of Philosophy, Rutgers University, New Brunswick, NJ, USA, Department of Health Behavior, Society and Policy, Rutgers School of Public Health, Piscataway, NJ, USA; Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
Tobias GerhardCenter for Pharmacoepidemiology and Treatment Science, Rutgers University, New Brunswick, NJ, USA, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA; Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
Brian L StromRutgers Biomedical and Health Sciences, Newark, NJ, USA. Electronic address: bstrom@rbhs.rutgers.edu.
Rutgers, The State University of New Jersey · US

Funding

Wellcome Trust 208766/Z/17/Z
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

COVID-19Viral VaccinesCOVID-19 VaccinesHumansPrior AuthorizationSARS-CoV-2COVID-19 VaccinesViral VaccinesAntibody dependent enhancementAssessment, Risk benefitCoronavirusEthicsPharmacoepidemiologyRandomized clinical trialsToxicityVaccines

Identifiers

PMID34023137
PMCPMC8084609
OpenAlexW3157951422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.